Utility of the National Lung Screening Trial Criteria for Estimation of Lung Cancer in the Korean Population.
- Author:
Ye Jin LEE
1
;
Sun Mi CHOI
;
Jinwoo LEE
;
Chang Hoon LEE
;
Sang Min LEE
;
Chul Gyu YOO
;
Young Whan KIM
;
Sung Koo HAN
;
Young Sik PARK
Author Information
- Publication Type:Original Article
- Keywords: Lung neoplasms; Screening; Korea
- MeSH: Cohort Studies; Humans; Korea; Lung Neoplasms*; Lung*; Mass Screening*; Mortality; Nutrition Surveys; Retrospective Studies; Tertiary Care Centers
- From:Cancer Research and Treatment 2018;50(3):950-955
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Screening forlung cancerin high-risk patients using the National Lung Screening Trial (NLST) criteria resulted in a decreased lung cancer-related mortality rate. However, whether these criteria are applicable to the Korean has not been investigated thus far. Therefore, we estimated the utility of the NLST criteria as a screening tool for lung cancer in the Korean population. MATERIALS AND METHODS: The total number of newly diagnosed lung cancer cases in 2013 was obtained from the Korea National Statistical Office. The proportion of newly diagnosed lung cancer cases that met the NLST criteria was calculated via a retrospective cohort of a tertiary referral hospital. We estimated the nationwide proportion of patients who met the NLST criteria using the 5th Korea National Health and Nutrition Examination Survey conducted during 2010-2012 (KNHANES V). RESULTS: Using KNHANES V data, we found that approximately 6.92% of the general population of Korea would meet the NLST criteria. In the tertiary referral hospital, 29.6% of the 2,689 newly diagnosed lung cancer patients met the NLST criteria. In 2013, the total number of newly diagnosed lung cancer cases in Korea was 23,177. The estimated nationwide proportions of lung cancer patients who met and did not meet the NLST criteria were 0.37% and 0.06%, respectively, yielding a ratio of 5.78. CONCLUSION: The NLST criteria demonstrated sound clinical utility for lung cancer screening of high-risk patients in Korea.
